Research and Markets: Biotechnology Pharmaceutical Market in US 2009-2013 Report Forecasts the Biotechnology Pharmaceutica

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a02aba/biotechnology_phar) has announced the addition of the "Biotechnology Pharmaceutical Market in US 2009-2013" report to their offering.

Biotechnology Pharmaceutical Market in US 2009-2013 report by Technavio Insights forecasts the Biotechnology Pharmaceutical market to grow at a CAGR of 7.7 percent, with Blood Modifiers accounting for the largest share of the market at 36.3 percent.

The major growth drivers include:

  • Increasing demand for biotechnology drugs with enhanced efficiency, safety and popularity
  • Revision of regulations and standards in favour of biotechnology drugs are encouraging more companies to invest in the field
  • Increasing ageing population and the prevalence of chronic and age related illnesses is also driving the demand for biotechnology pharmaceuticals

However, the market is faced with some challenges which can inhibit the growth, such as the increasing healthcare expenditure in the US. Many biotechnology pharmaceutical companies are facing cost containment pressure. Lack of technical development and expertise is an issue as these companies need to employ highly skilled medical professionals.

For the purpose of this report, the Biotechnology Pharmaceutical market refers to drugs, medicines or vaccines developed through biotechnology such as recombinant DNA technology, combinatorial chemistry, gene therapy, and monoclonal antibodies. The report analyzes Biotechnology Pharmaceutical markets recent performance and provides the US market revenue and growth rates from 2009 through to 2013. It also provides detailed market segmentation based on the type of disease the drugs are formulated to treat or based on therapeutic class. The report includes comprehensive analysis of various trends and changes taking place in the Biotechnology Pharmaceutical market in the US.

It also explains the factors influencing market growth and also inhibitors preventing their adoption. The report provides basic profiles of some of the leading vendors in the market

Key Topics Covered:

  • Introduction
  • Market Size and Forecast
  • Market Segmentation
  • Market Trends in Biotechnology Pharmaceutical in US
  • Market Drivers in Biotechnology Pharmaceutical in US
  • Market Challenges in Biotechnology Pharmaceutical in US
  • Vendors
  • List of Exhibits
  • Exhibit 2.1: Biotechnology Pharmaceutical in US Market Size and Forecast 2009-2013 (In $billion)
  • Exhibit 3.1: US Biotechnology Pharmaceutical Market Segmentation -2009

For more information visit http://www.researchandmarkets.com/research/a02aba/biotechnology_phar



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”